Source comparison
Follistatin-344 vs MK-677: Research Application Comparison
Primary Mechanism Myostatin inhibition via direct binding to GDF-8, preventing ActRIIB receptor activation Ghrelin receptor agonism stimulating pulsatile GH secretion from anterior pituitary Follistatin targets localized hypertrophy; MK-677 creates systemic an
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Myostatin inhibition via direct binding to GDF-8, preventing ActRIIB receptor activation
- Ghrelin receptor agonism stimulating pulsatile GH secretion from anterior pituitary
- Follistatin targets localized hypertrophy; MK-677 creates systemic anabolic conditions
- Administration Route
- Intramuscular injection into target muscle groups
- Oral administration (capsule or liquid)
- MK-677's oral bioavailability simplifies dosing; follistatin requires IM technique
- Typical Research Dose
- 100mcg–1mg per injection, 2–3× weekly
- 12.5–25mg once daily, preferably evening
- Follistatin uses intermittent dosing; MK-677 requires daily consistency
- Half-Life
- 28–32 hours
- 4–6 hours (with 24-hour GH elevation)
- Follistatin persists longer in tissue; MK-677's short half-life requires daily dosing
- Onset of Measurable Effects
- 10–14 days (muscle fiber hypertrophy)
- Hours (GH/IGF-1 elevation); 8–12 weeks (body composition)
- Follistatin produces rapid localized changes; MK-677's systemic effects require sustained use
- Primary Research Endpoints
- Muscle fiber cross-sectional area, localized hypertrophy, satellite cell activation
- Lean mass accrual, lipolysis, sleep quality, nitrogen retention, injury recovery
- Choose follistatin for muscle-specific studies; MK-677 for whole-body anabolism
- Systemic IGF-1 Elevation
- Minimal to none (localized effect only)
- 40–90% increase at 25mg daily dosing
- MK-677 elevates IGF-1 systemically; follistatin does not
- Adverse Event Profile
- Injection site discomfort, rare immune response to exogenous protein
- Increased appetite, transient insulin resistance, water retention
- Follistatin's risks are injection-related; MK-677's are metabolic
- Post-Administration Persistence
- Hypertrophic effects last 4–6 weeks after final dose
- Effects cease within 48–72 hours of discontinuation
- Follistatin's structural changes outlast the compound; MK-677 requires continuous use